ZNTL [NASD]
Zentalis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.85 Insider Own4.60% Shs Outstand45.00M Perf Week-21.83%
Market Cap1.23B Forward P/E- EPS next Y-4.71 Insider Trans-11.34% Shs Float31.80M Perf Month-13.15%
Income-167.90M PEG- EPS next Q-1.21 Inst Own80.70% Short Float13.59% Perf Quarter-56.53%
Sales- P/S- EPS this Y11.30% Inst Trans2.99% Short Ratio5.40 Perf Half Y-72.27%
Book/sh8.09 P/B2.56 EPS next Y-8.00% ROA-39.70% Target Price82.40 Perf Year-63.37%
Cash/sh5.74 P/C3.61 EPS next 5Y- ROE-47.70% 52W Range17.33 - 87.19 Perf YTD-75.34%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.22% Beta-
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin- 52W Low19.62% ATR2.70
Employees177 Current Ratio8.00 Sales Q/Q- Oper. Margin- RSI (14)38.68 Volatility11.66% 12.57%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.50% Profit Margin- Rel Volume0.47 Prev Close20.73
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 BMO Payout- Avg Volume800.17K Price20.73
Recom1.40 SMA20-10.73% SMA50-36.56% SMA200-64.39% Volume0 Change0.00%
Apr-06-22Initiated Wells Fargo Overweight $67
Oct-07-21Resumed Jefferies Buy $120
Sep-30-21Initiated Stifel Buy $84
Sep-29-21Initiated Oppenheimer Outperform $90
May-21-21Initiated UBS Buy $91
Jan-20-21Initiated Wedbush Outperform $65
Sep-29-20Initiated Cantor Fitzgerald Overweight $44
Aug-27-20Initiated H.C. Wainwright Buy $43
Apr-28-20Initiated SVB Leerink Outperform $45
Apr-28-20Initiated Morgan Stanley Overweight $45
Apr-28-20Initiated Jefferies Buy $41
Apr-28-20Initiated Guggenheim Buy $45
May-21-22 09:48AM  
May-18-22 04:01PM  
May-16-22 07:28AM  
07:00AM  
May-05-22 07:00AM  
Apr-27-22 10:17AM  
07:00AM  
Apr-19-22 09:35AM  
Apr-11-22 04:01PM  
07:22AM  
Apr-08-22 01:00PM  
Mar-29-22 07:00AM  
Mar-22-22 07:00AM  
Mar-09-22 04:01PM  
Mar-08-22 04:30PM  
Feb-24-22 07:00AM  
Feb-03-22 07:00AM  
Dec-22-21 10:15AM  
Dec-21-21 12:03PM  
Dec-14-21 11:15AM  
Dec-02-21 07:00AM  
Nov-17-21 11:35AM  
07:00AM  
Nov-10-21 07:00AM  
Nov-09-21 07:00AM  
Nov-08-21 10:07AM  
Nov-03-21 11:26AM  
Oct-25-21 12:04PM  
Oct-05-21 11:28AM  
Sep-13-21 07:00AM  
Sep-09-21 07:00AM  
Sep-02-21 07:00AM  
Sep-01-21 07:00AM  
Aug-12-21 07:00AM  
Aug-04-21 07:00AM  
Aug-02-21 07:30AM  
07:00AM  
Jul-28-21 01:15PM  
Jul-01-21 04:01PM  
Jun-29-21 06:54AM  
Jun-28-21 09:09PM  
04:18PM  
07:00AM  
Jun-22-21 07:16AM  
Jun-21-21 09:15AM  
May-28-21 07:00AM  
May-17-21 07:00AM  
Apr-20-21 08:00AM  
Apr-12-21 11:18AM  
07:00AM  
Apr-10-21 01:30PM  
Mar-25-21 07:00AM  
Mar-10-21 04:30PM  
Feb-25-21 07:00AM  
Feb-24-21 07:00AM  
Feb-10-21 07:00AM  
Feb-05-21 07:00AM  
Feb-04-21 08:41AM  
Jan-06-21 07:00AM  
Dec-23-20 05:20AM  
Dec-12-20 10:19PM  
Nov-12-20 07:00AM  
Nov-09-20 07:00AM  
Sep-23-20 01:59PM  
Sep-11-20 07:00AM  
Sep-10-20 07:00AM  
Sep-01-20 07:00AM  
Aug-13-20 07:00AM  
Jul-29-20 09:11PM  
Jul-27-20 04:19PM  
07:00AM  
Jul-01-20 07:00AM  
Jun-15-20 04:30PM  
Jun-03-20 07:07AM  
May-28-20 04:05PM  
07:00AM  
May-20-20 07:00AM  
May-15-20 07:00AM  
May-13-20 09:30AM  
Apr-30-20 07:00AM  
Apr-07-20 04:05PM  
Apr-02-20 09:22PM  
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bunker Kevin D.Chief Operating OfficerApr 11Sale30.555,000152,745135,000Apr 13 05:53 PM
Gallagher CamDirectorApr 05Sale50.4810,000504,769355,813Apr 05 06:52 PM
SUN ANTHONY YPresident & CEOApr 05Sale51.5210,471539,4741,175,589Apr 05 06:52 PM
SUN ANTHONY YPresident & CEOApr 04Sale48.5010,471507,8441,186,060Apr 05 06:52 PM
Epperly Melissa B,Chief Financial OfficerApr 04Sale50.0917,080855,522247,414Apr 05 06:53 PM
Bunker Kevin D.Chief Operating OfficerMar 21Sale49.0710,000490,670140,000Mar 21 07:55 PM
Gallagher CamDirectorMar 15Sale41.9210,000419,241365,813Mar 16 05:18 PM
Bunker Kevin D.Chief Operating OfficerMar 10Sale46.9410,000469,374150,000Mar 10 05:41 PM
Gallagher CamDirectorMar 07Sale44.9410,000449,387375,813Mar 08 07:43 PM
SUN ANTHONY YPresident & CEOMar 02Sale50.1610,471525,2651,196,531Mar 03 05:11 PM
SUN ANTHONY YPresident & CEOMar 01Sale49.7910,471521,3841,207,002Mar 03 05:11 PM
Epperly Melissa B,Chief Financial OfficerFeb 23Sale49.101,91393,921264,494Feb 23 08:12 PM
Bunker Kevin D.Chief Operating OfficerFeb 22Sale49.0910,000490,933160,000Feb 23 08:12 PM
Gallagher CamDirectorFeb 15Sale51.9310,000519,295385,813Feb 15 06:35 PM
Pinto AlexisChief Legal OfficerFeb 14Sale50.2369134,70822,240Feb 14 09:10 PM
Voliotis DimitrisSVP, Clinical DevelopmentFeb 14Sale50.2360130,18815,978Feb 14 09:10 PM
Gallagher CamDirectorFeb 14Sale50.197,188360,775395,813Feb 14 09:09 PM
SUN ANTHONY YPresident & CEOFeb 14Sale50.234,733237,7331,217,473Feb 14 09:08 PM
Bunker Kevin D.Chief Operating OfficerFeb 14Sale50.264,688235,638764,110Feb 14 09:11 PM
Bunker Kevin D.Chief Operating OfficerFeb 10Sale53.5010,000534,995170,000Feb 14 09:11 PM
Gallagher CamDirectorFeb 07Sale53.4510,000534,474387,203Feb 07 09:53 PM
SUN ANTHONY YPresident & CEOFeb 02Sale57.9710,471606,9661,171,775Feb 03 08:03 PM
SUN ANTHONY YPresident & CEOFeb 01Sale57.5810,471602,9261,182,246Feb 03 08:03 PM
Voliotis DimitrisSVP, Clinical DevelopmentJan 20Option Exercise18.0010,000180,00016,250Jan 20 07:15 PM
Bunker Kevin D.Chief Operating OfficerJan 20Sale59.9910,000599,912180,000Jan 20 07:14 PM
Voliotis DimitrisSVP, Clinical DevelopmentJan 20Sale60.6310,000606,3236,250Jan 20 07:15 PM
Voliotis DimitrisSVP, Clinical DevelopmentJan 19Option Exercise18.0010,000180,00016,250Jan 20 07:15 PM
Voliotis DimitrisSVP, Clinical DevelopmentJan 19Sale60.7910,000607,9316,250Jan 20 07:15 PM
Voliotis DimitrisSVP, Clinical DevelopmentJan 18Option Exercise18.0010,000180,00016,250Jan 20 07:15 PM
Gallagher CamDirectorJan 18Sale62.6410,000626,376397,203Jan 19 07:21 PM
Voliotis DimitrisSVP, Clinical DevelopmentJan 18Sale62.6510,000626,4916,250Jan 20 07:15 PM
Bunker Kevin D.Chief Operating OfficerJan 10Sale68.4110,000684,097190,000Jan 11 06:55 PM
Gallagher CamDirectorJan 05Sale75.4910,000754,861407,203Jan 05 05:49 PM
SUN ANTHONY YPresident & CEOJan 04Sale78.6810,471823,8701,192,717Jan 05 05:49 PM
Blackwell KimberlyDirectorJan 03Option Exercise47.801,00047,8006,000Jan 05 05:49 PM
Blackwell KimberlyDirectorJan 03Sale83.741,00083,7405,000Jan 05 05:49 PM
SUN ANTHONY YPresident & CEOJan 03Sale80.0710,471838,4381,203,188Jan 05 05:49 PM
Bunker Kevin D.Chief Operating OfficerDec 20Sale79.2410,000792,431200,000Dec 21 06:17 PM
Gallagher CamDirectorDec 15Sale74.0310,000740,337417,203Dec 16 05:18 PM
Bunker Kevin D.Chief Operating OfficerDec 10Sale71.7110,000717,106210,000Dec 13 06:09 PM
Gallagher CamDirectorDec 06Sale71.3310,000713,300427,203Dec 07 08:35 PM
SUN ANTHONY YPresident & CEODec 02Sale76.7810,471803,9921,103,659Dec 02 07:16 PM
Blackwell KimberlyDirectorDec 01Option Exercise47.801,00047,8006,000Dec 02 07:16 PM
SUN ANTHONY YPresident & CEODec 01Sale77.9810,471816,5361,114,130Dec 02 07:16 PM
Blackwell KimberlyDirectorDec 01Sale81.841,00081,8405,000Dec 02 07:16 PM
Bunker Kevin D.Chief Operating OfficerNov 22Sale75.9910,000759,937220,000Nov 23 04:45 PM
Gallagher CamDirectorNov 15Sale75.3610,000753,619437,203Nov 16 07:11 PM
Bunker Kevin D.Chief Operating OfficerNov 10Sale78.1510,000781,471230,000Nov 12 04:38 PM
Gallagher CamDirectorNov 05Sale82.9510,000829,491447,203Nov 05 09:12 PM
SUN ANTHONY YPresident & CEONov 02Sale80.4710,471842,6021,249,601Nov 02 07:24 PM
Blackwell KimberlyDirectorNov 01Option Exercise47.801,00047,8006,000Nov 02 07:24 PM
Blackwell KimberlyDirectorNov 01Sale80.461,00080,4605,000Nov 02 07:24 PM
SUN ANTHONY YPresident & CEONov 01Sale81.4410,471852,7721,260,072Nov 02 07:24 PM
Pinto AlexisChief Legal OfficerOct 25Option Exercise34.4030,0001,032,00036,526Oct 27 08:13 PM
Blackwell KimberlyDirectorOct 25Option Exercise47.801,00047,8006,000Oct 27 08:13 PM
Blackwell KimberlyDirectorOct 25Sale77.591,00077,5905,000Oct 27 08:13 PM
Pinto AlexisChief Legal OfficerOct 25Sale77.7330,0002,332,0026,526Oct 27 08:13 PM
SUN ANTHONY YPresident & CEOOct 04Sale66.3326,7991,777,7071,270,543Oct 04 09:15 PM
Johnson David MichaelDirectorOct 04Sale66.3512,896855,58880,959Oct 04 09:15 PM
Bunker Kevin D.Chief Operating OfficerOct 01Sale66.138,420556,8560Oct 04 09:16 PM
Gallagher CamDirectorOct 01Sale66.1510,000661,490457,203Oct 04 09:17 PM
SUN ANTHONY YPresident & CEOSep 01Sale67.5026,7941,808,7161,297,342Sep 02 07:32 PM
Gallagher CamDirectorSep 01Sale67.5210,000675,229467,203Sep 02 07:32 PM
Bunker Kevin D.Chief Operating OfficerSep 01Sale67.498,420568,2838,420Sep 02 07:31 PM
Epperly Melissa B,Chief Financial OfficerAug 19Buy52.008,285430,800266,685Aug 20 12:59 PM
Epperly Melissa B,Chief Financial OfficerAug 18Buy52.001,32668,948258,400Aug 20 12:59 PM
SUN ANTHONY YPresident & CEOAug 03Sale50.537,779393,0901,324,136Aug 03 08:01 PM
SUN ANTHONY YPresident & CEOAug 02Sale51.0319,015970,2471,331,915Aug 03 08:01 PM
Gallagher CamDirectorAug 02Sale51.0210,000510,198477,203Aug 03 07:59 PM
Bunker Kevin D.Chief Operating OfficerAug 02Sale51.058,420429,80516,840Aug 03 07:59 PM
SUN ANTHONY YPresident & CEOJul 07Sale47.1317,804839,1141,350,930Jul 08 04:56 PM
Gallagher CamDirectorJul 07Sale47.132,572121,220499,382Jul 08 04:55 PM
Bunker Kevin D.Chief Operating OfficerJul 07Sale47.134,514212,7481,008,788Jul 08 04:55 PM
Bunker Kevin D.Chief Operating OfficerJul 06Sale46.9020,298951,927994,841Jul 08 04:55 PM
Gallagher CamDirectorJul 06Sale46.8815,798740,636487,203Jul 08 04:55 PM
SUN ANTHONY YPresident & CEOJul 06Sale46.9025,0451,174,4881,368,734Jul 08 04:56 PM
Gallagher CamDirectorJul 02Sale49.5810,000495,827505,573Jul 06 08:00 PM
SUN ANTHONY YPresident & CEOJul 01Sale51.2126,7941,372,2351,393,779Jul 06 08:00 PM
Epperly Melissa B,Chief Financial OfficerJul 01Sale51.273,083158,054257,074Jul 06 08:01 PM
Bunker Kevin D.Chief Operating OfficerJul 01Sale51.238,420431,36725,260Jul 06 08:01 PM
Bunker Kevin D.Chief Operating OfficerJun 01Sale54.098,420455,44233,680Jun 02 08:26 PM
Gallagher CamDirectorJun 01Sale54.0610,000540,551515,573Jun 02 08:27 PM
SUN ANTHONY YPresident & CEOJun 01Sale54.0326,7941,447,6791,420,573Jun 02 08:26 PM
Epperly Melissa B,Chief Financial OfficerJun 01Sale54.053,083166,641260,157Jun 02 08:26 PM